FDA Expands Mounjaro Use for Heart Health
The U.S. Food and Drug Administration (FDA) has granted approval for Eli Lilly's diabetes medication, Mounjaro, to reduce the risk of major cardiovascular events such as heart attack and stroke. This significant expansion applies to adults living with type 2 diabetes who are also at a high risk for cardiovascular complications.
Previously authorized primarily for blood sugar regulation, Mounjaro's new indication underscores its broader therapeutic potential. The drug, which targets both GLP-1 and GIP incretin hormones, now offers a crucial protective benefit for a patient population where cardiovascular disease remains the leading cause of mortality.
Clinical Trial Highlights Mounjaro's Efficacy
The FDA's decision was based on compelling data from a large-scale head-to-head clinical trial. In this study, Mounjaro demonstrated superior efficacy compared to Trulicity, another of Eli Lilly's diabetes drugs, in reducing the incidence of major adverse cardiovascular events.
Trial results indicated that patients receiving Mounjaro experienced an 8% lower rate of heart attack, stroke, or heart-related death compared to those on Trulicity. Trulicity, which solely targets the GLP-1 hormone, had previously shown a 12% reduction in heart events versus placebo. Dr. Rachel Batterham, a senior vice-president at Lilly focusing on cardiometabolic health, highlighted the high standard set by comparing Mounjaro against an already beneficial treatment.
Competitive Landscape and Future Developments
Eli Lilly's move follows similar approvals for competitor Novo Nordisk's GLP-1 drugs. Novo Nordisk secured FDA approval for its weight-loss drug Wegovy in 2024 to lower heart risks in overweight or obese adults without diabetes. In 2025, their older diabetes drug Rybelsus also received an indication to reduce major heart risks in diabetic patients. While Mounjaro's trial design differs, other GLP-1 drugs like Ozempic and Wegovy are authorized to lower heart disease risk by 20%.
Mounjaro's obesity counterpart, Zepbound, is also undergoing studies to track heart events in individuals without type 2 diabetes. Eli Lilly continues to innovate, with ongoing late-stage studies for its oral obesity pill Foundayo concerning cardiovascular benefits, and its next-generation obesity drug retatrutide, which is being evaluated for its impact on cardiovascular events and kidney disease progression. The strong demand for Mounjaro has fueled significant growth, with sales surging 91% to $9.94 billion in the second quarter, according to recent reports.